European Biotech Acquisition Corp.
EBACU
NASDAQ Capital Market11.30
USD
+0.40
- -
CIK
0001841258
ISIN
KYG3167F1101
CUSIP
G3167F110
Return %
Stock
S&P500
1Y
14.72
18.21
3Y
13.00
64.38
5Y
13.00
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Eduardo Bravo Fernandez de Araoz
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- Johannes Vermeerplein 9 Amsterdam Netherlands 1071 DV
- IPO Date
- Mar 16, 2021
- CIK
- 0001841258
- Website
- lspvc.com
- Similar Companies
- Business
- European Biotech Acquisition Corp. (EBAC), ticker EBACU, operates as a blank check company, or special purpose acquisition company (SPAC), whose primary purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company focuses on identifying targets in the European life sciences industry, particularly those with high-potential therapeutic assets, breakthrough potential, strong management teams, near-term value inflection points and suitability for strategic exits via mergers and acquisitions; it offers no independent products or services beyond this acquisition vehicle. Founded in 2021 and headquartered in Amsterdam, Netherlands, with ties to LSP (now part of EQT Life Sciences), EBAC conducted its initial public offering in March 2021, raising approximately USD 120-127 million through 12 million units on Nasdaq Capital Market. In October 2022, EBAC announced a definitive business combination agreement with Oculis SA, a Swiss ophthalmology biotech developing eye disease therapies; the transaction closed via reverse merger on March 2, 2023, resulting in Oculis Holding AG as the combined public entity listed under tickers OCS and OCSAW, with EBAC ceasing independent operations thereafter. EBAC maintains affiliations with LSP's offices in Amsterdam, Munich and Boston, leveraging the firm's 30-plus years of healthcare investment expertise targeting innovative life sciences companies across Europe and the United States.